Evidence map›Paper›PMID 39843361›Full record

ArticleBMJ open gastroenterology2025

Triglyceride lowering in patients with different severities of hypertriglyceridaemia-associated acute pancreatitis: secondary analysis of a multicentre, prospective cohort study.

Xiang Luo, Xiaoling Li, Xiaoyan Lai, Wenjian Mao, Lu Ke, Lingyan Fu, Lin Gao, Yaolu Liu

Abstract readMulticenter Study
In one paragraph

Article in BMJ open gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiang LuoDepartment of Critical Care Medicine, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, Fujian, China.ORCID http://orcid.org/0009-0004-3784-1951
Xiaoling LiDepartment of Anesthesiology, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, Fujian, China.ORCID http://orcid.org/0009-0001-1800-4646
Xiaoyan LaiDepartment of Critical Care Medicine, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, Fujian, China.ORCID http://orcid.org/0009-0004-2980-6793
Wenjian MaoDepartment of Critical Care Medicine, Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China.ORCID http://orcid.org/0000-0002-0033-8939
Lu KeDepartment of Critical Care Medicine, Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China.ORCID http://orcid.org/0000-0001-8093-5073
Lingyan FuDepartment of Critical Care Medicine, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, Fujian, China.ORCID http://orcid.org/0009-0007-6028-637X
Lin GaoDepartment of Critical Care Medicine, Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China njuyixueyuangl@163.com yumojianke1@126.com.ORCID http://orcid.org/0000-0002-7016-4612
Yaolu LiuDepartment of Critical Care Medicine, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, Fujian, China njuyixueyuangl@163.com yumojianke1@126.com.ORCID http://orcid.org/0009-0008-9805-263X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveIt is controversial whether rapid lowering of triglyceride (TG) levels is associated with clinical benefits in patients with hypertriglyceridaemia-associated acute pancreatitis (HTG-AP). In particular, patients with different severity of disease may respond differently to TG-lowering therapy. In this study, we aimed to explore the association between rapid decline in serum TG levels and organ failure in patients with different severities of HTG-AP.

methodsThis is a secondary analysis of data from a multicentre, prospective registry recruiting HTG-AP patients admitted within 72 hours from the onset of symptoms. Patients were dichotomised into either target reaching (TG≤5.65 mmol/L on study day 3) or not. The primary outcome was the presence of organ failure at day 14. The association between target-reaching and the primary outcome was modelled. Furthermore, subgroup analyses were conducted based on the disease severity of HTG-AP patients at enrolment.

resultsOverall, 413 patients were included for analysis, of whom 192 (46.5%) reached the target on day 3. For the overall study cohort, there was no significant difference in presence of organ failure at day 14 between patients reaching the target or not (3.1% vs 6.8%, p=0.091). In the subgroup of HTG-AP patients with organ failure at enrolment, compared with patients with TG>5.65 mmol/L on day 3, patients who reached the target had significantly lower presence of organ failure at day 14 (7.8% vs 22%, p=0.039) and lower incidence of infected pancreatic necrosis within 60 days (3.1% vs 11.9%, p=0.049). Similar findings were seen in the subgroup with more severe HTG-AP (APACHE II ≥8 at enrolment).

conclusionMore rapid decline of serum TG levels was associated with decreased presence of organ failure at day 14 in patients with more severe HTG-AP. TRIAL REGISTRATION NUMBER: The Chinese Clinical Trial Registry, number ChiCTR2000039541.

Indexed as

HypertriglyceridemiaHypolipidemic AgentsPancreatitisTriglyceridesAcute DiseaseAdultAgedFemaleHumansMaleMiddle AgedMultiple Organ FailureProspective StudiesRegistriesSeverity of Illness IndexTreatment OutcomeHypolipidemic AgentsTriglyceridesACUTE PANCREATITISLIPIDSPANCREATIC DISORDERS

Identifiers

PMID39843361
PMCPMC11759208

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.